Crinetics Pharmaceuticals Inc.

CRNX

Held by 5 specialist biotech funds

High Convergence

Share on X

Fund Holdings

5 fund convergence

Baker Bros. Advisors Driehaus Capital OrbiMed Advisors

Catalysts

No catalysts tracked.

Position Details

Baker Bros. AdvisorsNEWFeb 17, 2026

Shares: 1,648,869Value: $76.8M

## Signal Note: Baker Bros. Initiates Large Position in CRNX **Note: The reported position value of ~$76.8B appears to be a data error—at recent prices (~$46-50/share), 1,648,869 shares would be worth approximately $76-82M, which is the likely actual position size.** Baker Bros. building a new ~$76-82M position in Crinetics is a high-conviction signal given their concentrated, specialist approach and strong track record in late-stage biotech. CRNX's lead asset **paltusotine**, an oral nonpeptide somatostatin receptor type 2 agonist, has a PDUFA date of **August 8, 2025** for **acromegaly**—positioning this as a pre-catalyst accumulation ahead of a potential first-in-class oral approval that could displace

Driehaus CapitalNEW

Know which insider moves are real

See who's buying with their own money vs. routine exercises
AI explains why each move matters right now

Start 7-Day Free Trial — $29/mo

Insider Signals

No insider signals tracked.

Also Held by These Funds

ALKS3 funds ARGX3 funds ARWR3 funds IRON3 funds PRAX3 funds EWTX3 funds SYRE3 funds INSM

Research Links

Yahoo Finance →SEC EDGAR →ClinicalTrials.gov →

Track specialist biotech funds, insider signals, and AI analysis

Start 7-Day Free Trial

Or get the free weekly brief:

# Signal Note: Driehaus Capital Initiates $297M Position in CRNX Driehaus's $297M entry into Crinetics likely reflects conviction in macrolithín (CRN04894), a oral selective somatostatin receptor 2 (SST2) agonist in Phase 3 for acromegaly, with topline data expected in 2H 2024. The timing aligns with potential near-term clinical readout that could validate oral SST2 agonists as a competitive alternative to current injectable therapies, de-risking the pipeline ahead of potential regulatory decisions in 2025.